CD79B and B-cell chronic lymphocytic leukemia: This also explains the lack of Igβ-targeting chimeric antigen receptor T cell studies in CLL therapy, although they show high efficacy in other B cell lymphomas, such as the diffuse large B cell lymphoma (DLBCL) (51).